Never Lose Hope! Lessons from CD20 depletion
Ritux (LUNAR) : Failed
Obinitizumab : NOBILITY (Phase II) and REGENCY (Phase III): Success
The now available REGENCY speaks volumes on
why science evolves. What fails today may succeed tomorrow! #LupusNephritis #Rheumtwitter
(1/3) x.com
Ritux (LUNAR) : Failed
Obinitizumab : NOBILITY (Phase II) and REGENCY (Phase III): Success
The now available REGENCY speaks volumes on
why science evolves. What fails today may succeed tomorrow! #LupusNephritis #Rheumtwitter
(1/3) x.com
How are these Molecules different ?
Rtx:Type I anti CD20; Chimeric ab ; Obinitizumab:Type II anti CD20, fully humanized ab x.com
Rtx:Type I anti CD20; Chimeric ab ; Obinitizumab:Type II anti CD20, fully humanized ab x.com
How are their MOA different ?
1. Rtx depends on Complement dependent cytotoxicity > ADCC ; Obinitizumab has more ADCC > CDC
2. Direct cell death by obinitizumab
3. Rituximab induced CDC, reduces CD20 expression on the B cells making them less accessible over time x.com
1. Rtx depends on Complement dependent cytotoxicity > ADCC ; Obinitizumab has more ADCC > CDC
2. Direct cell death by obinitizumab
3. Rituximab induced CDC, reduces CD20 expression on the B cells making them less accessible over time x.com
Loading suggestions...